GT Biopharma Corporation - GTBP Net Assets per Single Share

Patents for the TriKE platform create a powerful defensive barrier, requiring colossal investments and strict FDA oversight. The BVPS valuation allows for a verification of capital purity excluding write-downs, where the 2.00 mark characterizes this parameter. GT Biopharma, Inc. (GTBP) is fighting for leadership in NK-cell therapy against industry behemoths, while the absence of sales makes future pricing dependent on R&D outcomes.

To protect the portfolio, fundamental screening relies on the calculation of net assets minus liabilities, which determines the intrinsic value of the business per share. Amid geopolitical risks and supply chain vulnerabilities for GT Biopharma, Inc. (GTBP), analyzing the book value of a common share allows for an assessment of the company's actual tangible asset base, neutralizing the time lags associated with standard financial reporting.